Susan Galandiuk

Dr. Susan Galandiuk

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Surgery
Verified
Journal Article
Closed access
JCJane V. Carter
Jane V. Carter
JPJianmin Pan
Jianmin Pan
SRShesh N. Rai
Shesh N. Rai
SGSusan Galandiuk
Susan Galandiuk

26 May 2016 in Gut Pathogens
Verified
Journal Article
Open access
PDF file
AGAngela Glassing
Angela Glassing
SDScot Dowd
Scot Dowd
SGSusan Galandiuk
Susan Galandiuk
BDBrian Davis
Brian Davis
RCRodrick J. Chiodini
Rodrick J. Chiodini
The advent and use of highly sensitive molecular biology techniques to explore the microbiota and microbiome in environmental and tissue samples have detected the presence of contaminating microbial DNA within reagents. These microbial DNA contaminants may distort taxonomic distributions and relative frequencies in microbial datasets, as well as contribute to erroneous interpretations and identifications. We herein report on the occurrence of bacterial DNA contamination within commonly used DNA extraction kits and PCR reagents and the effect of these contaminates on data interpretation. When compared to previous reports, we identified an additional 88 bacterial genera as potential contaminants of molecular biology grade reagents, bringing the total number of known contaminating microbes to 181 genera. Many of the contaminants detected are considered normal inhabitants of the human gastrointestinal tract and the environment and are often indistinguishable from those genuinely present in the sample. Laboratories working on bacterial populations need to define contaminants present in all extraction kits and reagents used in the processing of DNA. Any unusual and/or unexpected findings need to be viewed as possible contamination as opposed to unique findings.

2 February 2017 in British Journal of Cancer
Verified
Journal Article
Open access
JCJane V Carter
Jane V Carter
NGNorman Galbraith
Norman Galbraith
DYDongyan Yang
Dongyan Yang
JBJames F Burton
James F Burton
SWSamuel P Walker
Samuel P Walker
SGSusan Galandiuk
Susan Galandiuk
Colorectal cancer (CRC) is common and associated with significant mortality. Current screening methods for CRC lack patient compliance. microRNAs (miRNAs), identified in body fluids, are negative regulators of gene expression and are dysregulated in many cancers, including CRC. This paper summarises studies identifying blood-based miRNAs dysregulated in CRC compared with healthy controls in an attempt to evaluate their use as a screening tool for the diagnosis of CRC. A search of electronic databases (PubMed and EMBASE) and grey literature was performed between January 2002 and April 2016. Studies reporting plasma or serum miRNAs in the diagnosis of CRC compared with healthy controls were selected. Patient demographics, type of patient sample (serum or plasma), method of miRNA detection, type of normalisation, and the number of significantly dysregulated miRNAs identified were recorded. Statistical evaluation of dysregulated miRNAs using sensitivity, specificity, and area under the curve (AUC) was performed. Thirty-four studies investigating plasma or serum miRNAs in the diagnosis of CRC were included. A total of 31 miRNAs were found to be either upregulated (n=17) or downregulated (n=14) in CRC cases as compared with controls. Fourteen studies identified panels of ⩾2 dysregulated miRNAs. The highest AUC, 0.943, was identified using a panel of 4 miRNAs with 83.3% sensitivity and 93.1% specificity. Meta-analysis of studies identifying a single dysregulated miRNA in CRC cases compared with controls was performed. Overall sensitivity and specificity of 28 individual miRNAs in the diagnosis of CRC were 76% (95% CI 72%-80%) and 76% (95% CI 72%-80%), respectively, indicating good discriminative ability of miRNAs as biomarkers for CRC. These data did not change with sensitivity analyses. Blood-based miRNAs distinguish patients with CRC from healthy controls with high sensitivity and specificity comparable to other common and invasive currently used screening methods for CRC. In future, miRNAs may be used as a relatively non-invasive blood-based marker for detection of CRC.

12 January 2012 in Human Mutation
Verified
Journal Article
Closed access
PDF file
ZKZiad Kanaan
Ziad Kanaan
SRShesh N. Rai
Shesh N. Rai
MEM. Robert Eichenberger
M. Robert Eichenberger
CBChristopher Barnes
Christopher Barnes
ADAmy M. Dworkin
Amy M. Dworkin
SGSusan Galandiuk
Susan Galandiuk
One of the most serious complications faced by patients with inflammatory bowel disease (IBD) is the potential development of colorectal cancer (CRC). There is a compelling need to enhance the accuracy of cancer screening of IBD patients. MicroRNAs (miRNAs) are small nonprotein‐coding RNAs that play important roles in CRC oncogenesis. In this study, we report differential miRNA expression in IBD patients with associated CRC from non‐neoplastic tissue to dysplasia and eventually cancer. In addition, we identify and examine the role of dysregulated miRNAs in the TP53 pathway. In our CD patients, six miRNAs were upregulated from non‐neoplastic tissue to dysplasia, but downregulated from dysplasia to cancer (miR‐122, miR‐181a, miR‐146b‐5p, let‐7e, miR‐17, miR‐143) (P < 0.001). Six differentially expressed miRNAs affected the TP53 pathway (miR‐122, miR‐214, miR‐372, miR‐15b, let‐7e, miR‐17) (P < 0.001). Using two human colon cancer cell lines (HT‐29 and HCT‐116), E2F1, an upstream regulator of TP53, was downregulated in both cell lines transfected with let‐7e (P < 0.05) as well as in HCT‐116 cells transfected with miR‐17 (P < 0.05). Additionally, cyclin G, a cell‐cycle regulator miR‐122 target was downregulated in both cell lines (P < 0.05). Unique differentially expressed miRNAs were observed in CD‐associated CRC progression. Six of these miRNAs had a tumorigenic effect on the TP53 pathway; the effect of three of which was studied using cell lines. Hum Mutat 33:551–560, 2012.

22 January 2007 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
NJN. S. Jafri
N. S. Jafri
SMS. S. Mahid
S. S. Mahid
KMK. S. Minor
K. S. Minor
SIS. R. Idstein
S. R. Idstein
CHC. A. Hornung
C. A. Hornung
SGSusan Galandiuk
Susan Galandiuk

1 April 2012 in Gastroenterology
Verified
Journal Article
Open access
PDF file
SGSusan Galandiuk
Susan Galandiuk
MRManuel Rodriguez-Justo
Manuel Rodriguez-Justo
RJRosemary Jeffery
Rosemary Jeffery
ANAnna M. Nicholson
Anna M. Nicholson
YCYong Cheng
Yong Cheng
TGTrevor Graham
Trevor Graham
Background & Aims Tumors that develop in patients with Crohn's disease tend be multifocal, so field cancerization (the replacement of normal cells with nondysplastic but tumorigenic clones) might contribute to intestinal carcinogenesis. We investigated patterns of tumor development from pretumor intestinal cell clones. Methods We performed genetic analyses of multiple areas of intestine from 10 patients with Crohn's disease and intestinal neoplasia. Two patients had multifocal neoplasia; longitudinal sections were collected from 3 patients. Individual crypts were microdissected and genotyped; clonal dependency analysis was used to determine the order and timing of mutations that led to tumor development. Results The same mutations in KRAS, CDKN2A(p16), and TP53 that were observed in neoplasias were also present in nontumor, nondysplastic, and dysplastic epithelium. In 2 patients, carcinogenic mutations were detected in nontumor epithelium 4 years before tumors developed. The same mutation (TP53 p.R248W) was detected at multiple sites along the entire length of the colon from 1 patient; it was the apparent founder mutation for synchronous tumors and multiple dysplastic areas. Disruption of TP53, CDKN2A, and KRAS were all seen as possible initial events in tumorigenesis; the sequence of mutations (the tumor development pathway) differed among lesions. Conclusions Pretumor clones can grow extensively in the intestinal epithelium of patients with Crohn's disease. Segmental resections for neoplasia in patients with Crohn's disease might therefore leave residual pretumor disease, and dysplasia might be an unreliable biomarker for cancer risk. Characterization of the behavior of pretumor clones might be used to predict the development of intestinal neoplasia.